Alterity Therapeutics-ADRATHE
13F holders, Q2 2024 (June 30)10holders
1new positions
2sold out
$1.81avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Alterity Therapeutics-ADR (ATHE) in their 13F filings, unchanged from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were Morgan Stanley ($88K), Susquehanna International Group, LLP ($42K) and Twin Lakes Capital Management, LLC ($11K).
- Company
- Alterity Therapeutics-ADR
- CUSIP
- 02155X205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $42K |
| Exits | 2 | $73K |
All 13F filers, Q1 2024 → Q2 2024: 23,311 shares bought and 39,294 shares sold, net −15,983 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Morgan Stanley | 0.00% | Reduce -6.9% | 48,395 | $88K |
| Susquehanna International Group, LLP | 0.00% | New | 23,311 | $42K |
| Twin Lakes Capital Management, LLC | 0.01% | No change | 5,925 | $11K |
| Providence Capital Advisors, LLC | 0.00% | No change | 200 | $362 |
| Osaic Holdings, Inc. | 0.00% | No change | 81 | $145 |
| Sugarloaf Wealth Management, LLC | 0.00% | No change | 33 | $60 |
| CoreCap Advisors, LLC | 0.00% | No change | 21 | $38 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 6 | $11 |
| Coppell Advisory Solutions LLC | 0.00% | — | 5 | $9 |
| UBS Group AG | 0.00% | No change | 2 | $4 |
"% of holder's portfolio" is ATHE's weight in each manager's 13F, not the share of Alterity Therapeutics-ADR the manager owns.